Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma We assessed ...
We conducted a retrospective, country-level study integrating GLOBOCAN 2022 incidence and mortality data, ClinicalTrials.gov records (2004-2025), and socioeconomic indicators (United Nations ...
Ballad Health reduced all-cause mortality by 22% and lowered its observed-to-expected mortality ratio by 10% between fiscal years 2023 and 2025. This progress is more than an operational win. It ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results